Biocept, Inc. (NASDAQ: BIOC) is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer.
Welcome to Traders News Source,
Stay tuned and keep an eye on your inbox for our next hot Small-Mid Cap stock report coming soon.
Do not forget to add us to your preferred/safe senders list within your email service provider.
Text the word “Traders” to the number “25827” from your cell phone to receive small cap reports in real-time ahead of the crowd.
BIOC’s liquid biopsy assays can be particularly useful when there is insufficient sample material to perform a tissue biopsy or when a tissue biopsy has proven inadequate for identifying actionable biomarkers required to support the use of targeted drug therapy. The overall Liquid Biopsy Market Estimated at $10+ Billion and has extreme Potential to improve cancer patient outcomes.
Anticipated Near-Term Milestones:
- Continue to grow commercial liquid biopsy volume and revenue
- enter into strategic sales and technology partnerships – Global and U.S.
- Sign additional Empower TC agreements with pathologists and major hospitals
- Launch blood collection tubes under VWR marketing & distribution agreement
- Sign new third-party health plan agreements and expand the relationship with BCBS
- Launch additional oncology biomarker assays and publish clinical case studies
The company is rapidly progressing towards full-fledged commercialization stage with significant upside potential, as its liquid biopsy tests begin to supplement or even replace tissue biopsies in the multi-billion molecular oncology testing market.
Analysts tracking the stock believes that Biocept is an emerging player in the liquid biopsy space and the key for Biocept is to continue to raise awareness about its technology platform. Furthermore, 2018 is expected to be a remarkable year for biotech space and oncology/cancer segment will likely continue to dominate the industry.
Several brokerage firms have initiated coverage on the company, and the stock currently has an average rating of “Buy” and a consensus price target of $2.50. Considering present valuation, the company is in a favorable risk-reward position, and value investors should consider exposure in this sector as the backdrop remains exceptionally favorable.
Description & about the Company:
Biocept is a cancer diagnostics company, which develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Traditional Biopsies, are invasive, can be painful, and difficult to carry out in many instances. On the flip side, Biocept’ detect circulating cells and the DNA fragments in blood, as opposed to from a direct tumor sample. The tests are called liquid biopsies.
Upcoming presentations:
- Biomarker Summit: The company would be making a presentation of analytical and clinical data for its Target Selector™ liquid biopsy assay platforms at the GTCbio 11th Biomarker Summit being held March 27-28, 2018 in San Diego. In these data sets BIOC, will demonstrate the ability of its circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) platforms to detect predictive and prognostic biomarkers from a simple blood sample.
The company aims to help physicians identify clinically actionable biomarkers as rapidly as possible with its Target Selector CTC and ctDNA platforms to enable timely and better-informed treatment selection.
- 2018 American Association for Cancer Research (AACR) Annual Meeting: The company is also scheduled for poster presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting being held April 14-18, 2018 in Chicago at McCormick Place North/South.
- Financial results for 2017: The company will release its financial results for the three months and 12 months ended December 31, 2017, after the market closes on Wednesday, March 28, 2018.
Unique differentiating factors of Biocept:
Q-3 Financial Results:
Revenue: Revenues for the third quarter of 2017 increased 6% to $1.1 million, from $1.0 million for the third quarter of 2016, and included $1.0 million in commercial test revenues and $67,000 in development services test revenues.
Profitability: The net loss for the third quarter of 2017 was $5.8 million, or $0.20 per share on 29.6 million weighted-average shares outstanding. This compares with a net loss for the third quarter of 2016 of $4.7 million, or $0.57 per share on 8.4 million weighted-average shares outstanding.
Liquidity and financial flexibility: Cash and cash equivalents were $5.9 million as of September 30, 2017, compared with $4.6 million as of December 31, 2016.
Key Stock Influences:
Successful completion of the upcoming milestones would lead future direction for the company. Any adversities related to these upcoming milestones might adversely impact the overall investor sentiments.
BIOC is still an early stage entity and has not yet generated meaningful revenue and will likely operate at a loss as it grows its market position and seeks ways to monetize it.
BIOC has a history of operating losses. Therefore, any time or cost overrun in its ongoing R&D activities and its impact on business & financial profile will remain a key business sensitivity factor.
Stock Chart:
On Wednesday, March 21st, 2018, BIOC is trading at $0.32 on an above average volume of 2.4 million shares exchanging hands. Market capitalization is $20.349 million. The current RSI is 44.55
In the past 52 weeks, shares of BIOC have traded as low as $0.26 and as high as $2.45
At $0.32, shares of BIOC are trading below its 50-day moving average (MA) at $0.40 and below its 200-day MA at $0.94
The present support and resistance levels for the stock are at $0.30 & $0.35 respectively.
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
